[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100220917":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":28,"locations":33,"responsibleParty":54,"collaborators":28,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":28,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":28,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":80,"whyStopped":28,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"HBsAg + adjuvant 1 Group","EXPERIMENTAL","Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).",[13],"Procedure: Blood Sampling",{"label":15,"type":10,"description":16,"interventionNames":17},"HBsAg + adjuvant 2 Group","Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"HBsAg + adjuvant 3 Group","Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Blood Sampling","Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).",[9,15,19],null,[30],{"name":31,"affiliation":5,"role":32},"GSK Clinical Trials","STUDY_DIRECTOR",[34,46],{"facility":35,"status":28,"city":36,"state":28,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":28},"GSK Investigational Site","Brussels","1200","Belgium","BE",{"type":41,"coordinates":42},"Point",[43,44],4.34878,50.85045,{"lat":44,"lon":43},{"facility":35,"status":28,"city":47,"state":28,"zip":48,"country":38,"countryCode":39,"cosmosGeoPoint":49,"geoPoint":53,"contacts":28},"Ghent","9000",{"type":41,"coordinates":50},[51,52],3.71667,51.05,{"lat":52,"lon":51},{"type":55,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100220917","phase-1-study-to-evaluate-the-persistence-of-the-cellular-and-humoral-immune-response-following-vaccinations-with-glaxosmithkline-gsk-biologicals-candidate-vaccines-containing-hbsag-and-different-adjuvants-in-healthy-adult-volunteers-100220917",false,"NCT02153320","Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers","A Long-term Follow-up of a Phase I\u002FII Study to Compare the Persistence and to Perform in Depth Characterisation of the Cellular and Humoral Immune Response Following Vaccinations With GSK Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Subjects who the investigator believes can and will comply with the requirements of the protocol.\n* Subjects who took part in and completed study 287615 (NCT00508833).\n* Written informed consent obtained from the subject.\n* Healthy subjects as established by medical history before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the blood sampling, or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to the blood sampling.\n* Administration of immunoglobulins within the three months preceding the blood sampling or planned administration during the study period.\n* Pregnant or lactating female.\n* Documented HIV-positive subject.",true,"ALL","22 Years","45 Years",{"count":68,"type":69},93,"ACTUAL","INTERVENTIONAL",[72],"PHASE1","The purpose of this long-term follow-up study was to evaluate the persistence of the cellular and the humoral immune response 4 years after the first dose of GSK Biologicals' investigational vaccine formulations containing HBsAg (used as a model antigen) and an adjuvant.",[75],"Hepatitis B",[77,78,79],"HBsAg","Persistence of the immune response","Adjuvants","COMPLETED","2017-05-24",{"date":83,"type":69},"2017-05-30",{"date":85,"type":69},"2005-09-05",{"date":87,"type":69},"2005-10-28",{"name":5,"class":6},2]